Anagrelide(Agrylin)

Anagrelide was first approved for marketing in the United States in 1997. It is a prescription drug targeting phosphodiesterase 3 (PDE3) and must be used strictly in accordance with medical advice.

Target of Action

Phosphodiesterase 3 (PDE3)

Mechanism of Action

This product inhibits the activities of phospholipase A2 and phosphodiesterase type 3 (PDE) in platelets, leading to an increase in the concentration of cyclic adenosine monophosphate (cAMP). At doses significantly higher than those required to induce thrombocytopenia, this elevation of cAMP concentration may exert an antiplatelet aggregation effect on platelets.

Dosage and Administration

Route and frequency of administration for Anagrelide: 0.5 mg four times a day, or 1 mg twice a day.

The dosage of Anagrelide needs to be adjusted according to the patient's actual condition. For specific circumstances, patients should consult a doctor and follow the medical advice strictly.

Recommended reading: Dosage and Administration of Anagrelide

Adverse Reactions

Serious adverse reactions: Decreased left ventricular ejection fraction, symptoms of heart failure, and other cardiovascular effects.

Reference article: Adverse Reactions of Anagrelide

Use in Special Populations

Pregnancy: Pregnancy Category C.

Lactation: It is unknown whether Anagrelide is excreted in human milk. Given the potential risk to the nursing infant, either breastfeeding should be discontinued or the product should be withdrawn.

General Precautions

1. Females who are pregnant, planning to become pregnant, or planning to breastfeed must inform the clinician. Females of childbearing potential are advised to avoid pregnancy and use effective contraceptive measures during Anagrelide treatment. If pregnancy occurs, the patient should be informed of the potential risks to the fetus.

2. Patients must inform the clinician if they are receiving or planning to receive concomitant therapy (including prescription and over-the-counter drugs) or have any concomitant diseases (e.g., liver disease).

3. Patients should be informed of other important preventive information.

FDA，2021.10